

Index

Note: National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research is abbreviated to Commission

- 22q11 deletion syndrome 372, 429
- 5HTT genotype *see* serotonin transporter gene
- acquisition 407
- activation ratio 220, 428
- actively translating ribosomes 218, 429
- additive factors logic 285
- adenine 429
- adenosine triphosphate (ATP) 298, 300
- ADHD *see* attention deficit/hyperactivity disorder
- adolescent alcohol use disorder (AUD)
- cognitive deficits 235
 - comorbid disruptive behavior disorders 234
 - dangers of lifetime dependence 232
 - diagnosis of, problems with 234
 - functional brain abnormalities 236–8
 - leading to abuse of other drugs 232–4
 - pathophysiology of 232
 - structural brain abnormalities 236
- alcohol 229
- prenatal exposure
 - behavioral and cognitive consequences 229–30
 - morphological consequences 230–2
 - see also* adolescent alcohol use disorder (AUD)
- allele 429
- amino acids 429
- amygdala (AMY) 81
- anxiety and depressive disorders 187, 188–9
 - approach-avoidance behaviors 58–9
 - autism studies 131
 - bipolar disorder 172–3
 - emotion regulation 39–40, 45–6
 - face processing 82–4, 189, 191–3
 - fear/threat response 185–6
 - fragile X syndrome 224
 - and *HTTLPR* genotypes 377–8
 - and intrinsically dangerous stimuli 186
 - schizophrenia 152–3
 - social phobia 189
- Analysis of Functional NeuroImages (AFNI), software 401
- Analyze, software platform 401
- ancestry informative markers (AIMs) 369, 429
- animal studies
- alcohol withdrawal 235
 - cocaine exposure in utero, effects of 337
 - developmental changes 395–6
 - dopamine, prefrontal cortex and working memory 371
 - drug use, causative relationship 233–4
 - eating behaviors, role of neuropeptides 249
 - emotional modulation of behavior 184–6
 - goal-directed behaviors 55
 - stimulus-response learning 210
- anisotropic diffusion 317, 407
- anorexia nervosa (AN) 245
- functional neuroimaging studies
 - receptor imaging studies 250–2
 - task-activation studies 250
 - phenotype of 245
 - risk factors
 - congenital risks 248
 - during development 248–9
 - genetic influences 247–8
 - serotonin and dopamine levels 247
 - trait behaviors 248
 - structural brain imaging studies 249

- anxiety and depressive disorders 183
 electrophysiology 194–5
 functional magnetic resonance imaging 188
 data in adults 188–91
 data in juveniles 191–4
 goal of brain imaging research 184–5
 magnetic resonance spectroscopy (MRS) 194
 morphometry 187
 data in adults 187–8
 data in juveniles 188
 neural circuits and behavior in anxiety and
 depressive disorders 186–7
 neural circuits in emotionally modulated behavior 185
 brain response to rewards 186
 brain response to threats 185–6
 relevant conditions 183
 anxiety disorders 183–4
 depressive disorders 184
 identifying at-risk juveniles 184
see also depression; stress reactivity
 approach and avoidance behavior 54–5
 frontal EEG asymmetry model 44
 role of amygdala 58–9
 role of prefrontal cortex (PFC) 59–60
 role of striatum 57–8
see also goal-directed behavior
 arithmetic processing, effect of decreased fragile X mental
 retardation gene protein (FMRP) 223
 array coils 330, 409
 arterial spin labeling (ASL) perfusion MRI 326, 407
 atypical development and childhood diseases, studies of
 adolescents exposed to cocaine in utero 337–8
 autism spectrum disorders 339
 sickle cell disease 338–9
 benefits of ASL for developmental neuroscience 330–1
 cerebral blood flow (CBF) quantification in age
 groups and longitudinal stability 331–2
 perfusion MRI for developmental fMRI studies 332–3
 methodological background 326–8
 normal development of CBF from childhood to
 young adulthood 334–7
 potential and challenges of 339–40
 relationship with other neuroimaging
 modalities 333–4
 spin labeling schemes 328
 technological advances 330, 391
 arterial transit time 328, 330, 407
 ASDs *see* autism spectrum disorders (ASDs)
 assent *see* child assent (informed consent)
 association, genetic 367, 429
 attention 120–1
 ADHD functional neuroimaging studies 121–3
 executive attention 121, 122–3
 selective attention 22, 120, 121–2
 sustained attention 120, 121
 attention deficit/hyperactivity disorder (ADHD) 113
 clinical phenomenology and epidemiology 113
 functional imaging 114–15
 attention 120–1
 developmental considerations 123
 functional neuroimaging results 121–3
 response inhibition 115
 developmental considerations 119
 functional neuroimaging results 115–19
 resting state studies 124
 studies of other activation tasks
 motor overflow 123
 reward processing 124
 spatio-visual attention 123
 timing deficits 123–4
 working memory (WM) 119
 functional neuroimaging results 119–20
 future research directions 126
 methylphenidate (MPH) effects 395
 neurobiology of 113–14, 124–5
 altered anatomical connectivity 125
 neurochemical perturbation 125
 structural anomalies 125, 390
 results of studies, challenges of integrating 125–6
 structural imaging 114, 351
 AUD *see* adolescent alcohol use disorder (AUD)
 auditory oddball paradigm, ERP 92–3, 355
 authorization, written release for pediatric research 271
 autism spectrum disorders (ASDs) 130
 anatomical imaging studies 314
 diffusion tensor imaging (DTI) 132–3
 structural MRI 131–2
 association with fragile X syndrome 218, 225
 brain overgrowth 131, 142, 390
 functional brain imaging
 activation studies 137
 exceptional abilities 142
 language stimulation studies 137–8
 mirror neuron system 140–2
 social perception and mentalizing studies
 eye gaze perception 140
 face perception 138–9
 mentalizing 140

- theory of mind 139–40
 - voice perception 139
- ASL perfusion MRI 339
 - resting state studies 136–7
- future directions for research 143
- magnetic resonance spectroscopy (MRS) 133–6
- social impairments, neurobiology of 143
- avoidance behavior *see* approach and avoidance behavior
- B_0 407
- B_{\max} 407–8
- B'_{\max} 408
- b value 319, 323, 407, 412
- balancing selection 373, 429
- basal ganglia
 - effect of psychotropic medication 175
 - excess glutamatergic activity in bipolar disorder 175, 310
 - inconsistent findings in major depressive disorder (MDD) 187–8
 - less activation in attention deficit/hyperactivity disorder (ADHD) 121–2
 - smaller in obsessive-compulsive disorder (OCD) 205–6
- base, genetic term 429
- base pair (bp) 429
- Belmont Report (National Commission) 274–5
- binding potential 408
- biological motion 73, 74, 81, 82
- biomarkers 344
 - potential type 346
 - olanzapine for bipolar disorder 357
 - paroxetine treatment for obsessive-compulsive disorder (OCD) 361
 - stimulants for attention deficit/hyperactivity disorder (ADHD) 355
 - and therapeutics development 396–7
- Biomedical Imaging Resource (BIR) 401
- Biomedical Informatics Research Network (BIRN) 392, 404
- bipolar disorder (BD) 161
 - clinical features of 161–71
 - future research directions 178–9
 - glutamatergic functioning 310
 - mood-stabilizing medication, effects of 176–7
 - neurodevelopmental cortico-limbic model 171–2, 178, 390
 - amygdala dysfunction 172–3
 - hippocampus 174
 - striatum abnormalities 174–5
 - ventral prefrontal cortex (VPMC) dysfunction 175–6
 - overlapping disorders, distinguishing from 178
- block designs 191, 284, 408
- blood–brain partition coefficient of water 331, 408
- B_{\max} 407–8
- BOLD (blood-oxygen-level-dependent) contrast
 - 281–2, 408
- BOLD (blood-oxygen-level-dependent) effect 408
- BOLD fMRI 281
 - combining with diffusion tensor imaging (DTI) 320–1
 - compared to perfusion fMRI 332–3
 - and concurrent arterial spin labeling (ASL)
 - perfusion MRI 333–4
 - longitudinal studies, test-retest reliability 394
 - need for longitudinal studies 393
 - for real-time therapy and neurofeedback 397
 - technological advances 391
 - test-retest reliability 393–4
 - see also* functional magnetic resonance imaging (fMRI)
- brain development
 - cortical expansion 10–12
 - models of normal function 394
 - results of neuroimaging studies 149–50
 - schizophrenia as a disorder of 148–9
 - studies of atypical 395–6
- brain functioning, differential effect of
 - pharmacotherapy vs. psychotherapy 397
- BrainVISA, software platform 401–2
- BrainVoyager, software 402
- Brownian motion 315, 408, 411
- bulimia nervosa (BN)
 - functional neuroimaging studies
 - receptor imaging studies 252–4
 - task activation studies 252
 - phenotype of 245–6
 - risk factors
 - congenital risks 248
 - early sexual maturation 249
 - genetic influences 247–8
 - serotonin (5HT) 247
 - trait behaviors 248
 - structural brain imaging studies 249
- capillary water permeability 408
- carbon-13 (^{13}C) MRS 301–2, 310, 408
- CASL *see* continuous arterial spin labeling (CASL)
 - perfusion imaging ASL
- catechol-*O*-methyltransferase (COMT)
 - COMT gene and inherited variations 369–70
 - effects on functional neuroimaging measures

- catechol-*O*-methyltransferase (COMT) (cont.)
 COMT haplotype predicts cortical efficiency 373
Val158Met predicts measures of frontal function 373
Val158Met and frontal cognition
 prediction of cognitive performance in varied groups 371–2
 regulation of dopamine level in prefrontal cortex (PFC) 371
Val158Met and stress resiliency 374
 balancing selection: warrior vs. worrier 373
 stressful stimuli and brain activation 374–5
- caudate nucleus (CN)
 activation
 increased activation in obsessive-compulsive disorder (OCD) 208–9
 increased during suppression of tics 207
 increased by methylphenidate medication in attention deficit/hyperactivity disorder (ADHD) 351
 underactivation in ADHD 116
- volumetric reduction
 in ADHD subjects 114, 389
 in fetal alcohol syndrome/fetal alcohol spectrum disorders (FAS/FASD) subjects 230
 in Tourette syndrome 203
see also striatum
- CBT *see* cognitive behavioral therapy (CBT)
- Center for Computational Biology (CCB) 392, 404
- cerebellum
 activation
 in autistic subjects 138
 in fragile X-associated tremor/ataxia syndrome (FXTAS) subjects 224
 prenatal development, effects of alcohol on 229
 vermian hypoplasia in autism 131
 volumetric reduction
 in ADHD 351
 in adolescent alcohol use disorder (AUD) 235
 in fragile X syndrome and FXTAS 222, 230
 in schizophrenia 155
- cerebral blood flow (CBF) 326, 409
 activation studies, autism 137–42
 after methylphenidate treatment 350
 measurement of using arterial spin labeling (ASL) perfusion MRI 326–7
 in adolescents exposed to cocaine in utero 337–8
 in different age groups 331–2
 in sickle cell disease 338–9
 and longitudinal stability 332
 normal development 334–7
 normal development 334–7
 quantification in age groups and longitudinal stability 331–2
see also regional cerebral blood flow (rCBF)
- cerebral metabolic rate of glucose (CMRglu) 121, 136, 409
- chemical shift 409
- chemical shift imaging (CSI) 302, 391, 409
- child assent (informed consent) 270–1
- chromosome 429
- chromosome 22q11 deletion syndrome 372, 429
- chronometry 285, 409
- clearinghouse 392, 403–4
- cocaine, effects of in utero exposure to 337–8
- co-causality 429
- co-dominant alleles 369–70, 375, 429
- codon 429
- cognitive ability
 deficits in
 attention deficit/hyperactivity disorder (ADHD) 235
 schizophrenia 147–8, 371
 substance use disorders (SUDs) 235
 differences in, pediatric research 288–9
 effects of *COMT Val158* genotype 371
 link to morphology 16–17
see also intelligence
- cognitive behavioral therapy (CBT)
 effects on brain function 347
 for OCD and effect of selective serotonin reuptake inhibitors (SSRIs) 357–61
- cognitive control 22
 future directions 33–4
 in schizophrenia 152
 neural substrates of 23–4
 neurodevelopmental changes
 error- and feedback-based performance adjustments 29–31
 interference suppression 24–7
 manipulation 27
 relational reasoning 31–3
 response inhibition 27–8
 response selection 28–9
 working memory 24
- neuroimaging studies 149–50
- processes 22–3
 and study of neurodevelopmental disorders 34
- coil loading 410
- coils 409–10

- Common Rule, regulation on human subjects research 267
- complex diseases 367, 369, 430
- compulsions, differentiating from complex tics 206
- COMT *see* catechol-*O*-methyltransferase (COMT)
- concordance 430
- concordance ratio 430
- consequentialism 274–5
- continuous arterial spin labeling (CASL) perfusion imaging ASL 328, 332, 410
- contrast 410
- contrast agents 326, 410
- convolution 410
- corpus callosum (CC)
- abnormalities in fetal alcohol syndrome (FAS) 230
 - reduced volume and fractional anisotropy (FA) in autism 131, 133
 - reduced volume in Tourette syndrome (TS) 203
 - volumetric reduction in attention deficit/hyperactivity disorder (ADHD) 114
- cortical pattern matching (CPM) 410
- normal morphological maturation 7–9
 - and brain surface asymmetry 12–15
 - and cortical expansion 10–12
 - and gray matter density (GMD) 9–10
 - and subcortical growth 15
- cortical thickness 410
- in peri-Sylvian region 9, 16
 - link to phonological processing skills 17, 104
 - and intelligence 17, 87
 - see also* gray matter density (GMD)
- cortisol secretion
- healthy adults and children 46–7
 - in depressed individuals 47
- creatine/phosphocreatine (Cr) 297–8, 410–11
- cytosine (C) 430
- cytosolic choline compounds (Cho) 297–8, 411
- changes with age 306
- databases
- Biomedical Informatics Research Network (BIRN) 392, 404
 - National Database for Autism Research (NDAR) 392, 403
 - NIH Pediatric MRI Data Repository 393, 403
 - Single Nucleotide Polymorphism database (dbSNP) 369
- decision-making 55–6
- fMRI paradigms of reward-related 60–1
 - fMRI studies of adolescent 61
 - global analysis of processes involved in 61
 - outcome analysis 68–9
 - preference formation/selection 68
 - reward anticipation 61–8
- fractal triadic model 56–60
- neural correlates of 124
- deconvolution 411
- default networks 285–6, 395, 411
- demethylation 430
- deontological theories of ethics 274
- deoxyribonucleic acid (DNA) 365, 430
- dephasing and dephasing spins 411
- depression 184
- brain glucose metabolism 347
 - neurobiology of 44–6
 - neuroendocrinology of 47
 - and serotonin transporter gene 375–8
 - see also* anxiety and depressive disorders; bipolar disorder (BD)
- depth-resolved surface coil spectroscopy (DRESS) 302, 411
- design *see* experimental design
- developmental clinical neuroscience 387
- atypical development, understanding 395–6
 - biomarker and therapeutics development 396–7
 - contributions of neuroimaging
 - normal development 388–9
 - psychiatric disorders 389
 - neuroethics 397–8
 - normal development, understanding 393–5
 - rationale for developmental approach 387–8
 - technological advances
 - imaging modalities 391–2
 - neuroinformatics 392–3
- diffusion 411
- MRI measurement of 316–17
- diffusion anisotropy 317, 407
- diffusion coefficient 411
- diffusion tensor 316, 411
- diffusion tensor imaging (DTI) 290, 314–15, 411–12
- autism studies 132–3
 - conventional DTI studies in adults, limitations of 319
 - DTI studies in children 321–3
 - fiber tractography 317–18
 - MR imaging parameters 319
 - MRI measurement of diffusion 316–17
 - multimodal combination of DTI with fMRI 320–1
 - non-conventional DTI 319–20
 - principles of 315
 - schizophrenia, neural connectivity 151
 - technological advances 391

- diffusion-weighted imaging (DWI) 412
 high *b* value for tissue structural characterization 323
- diplotype 430
- discourse comprehension, neural underpinnings
 of 99–100
- disruptive behavior disorders (DBD), comorbid
 with AUD 234
- dizygotic twin 430
- dopamine (DA)
 and ADHD
COMT genotype and working memory 372
 genes implicated in 113–14
 response to stimulant medication 347–50
 transmission deficits 123, 125
 amygdala nuclei regulating release of 59
COMT genotype
 chromosome 22q11 deletion syndrome 372
 and cognitive function in healthy children 371–2
 modulating dopamine transmission in prefrontal
 cortex 371
 risk factor in eating disorders 247
 and striatum
 abnormal dopamine transmission in Tourette
 syndrome and obsessive-compulsive
 disorder 201–3
 reward processing 186, 206
- Doppler ultrasound 330, 412
- dorsal and ventral systems, role in emotion regulation 45
- dorsolateral prefrontal cortex (DLPFC)
 emotion regulation 40
 and feedback-based learning 30–1
 increased gray matter volume following paroxetine
 treatment 361
 interference suppression 27
 and limbic inhibition 45
 and manipulation 27
 and regional cerebral blood flow in adults with
 obsessive-compulsive disorder 209
 and relational reasoning 31–3
 response selection 115
 working memory in schizophrenia 152
- drugs *see* illicit drug use; substance use disorder (SUD)
- eating disorders (EDs) 245
 brain imaging studies
 functional neuroimaging 250–4
 structural and resting-state metabolic
 neuroimaging 249
 phenotypes of 245
- risk factors 246
 childhood developmental factors 248–9
 congenital risks 248
 dopamine (DA) 247
 genotype 247–8
 hormonal and neuropeptide influences 247
 serotonin (5HT) 247
 trait behaviors 248
- echo 412
- echo time (TE) 412
- echo-planar imaging (EPI) 412
- eddy currents 412
- educational resources 401
- eigenvalues (of a diffusion tensor) 317, 412
- eigenvector (of a diffusion tensor) 317–18, 412–13
- electrophysiology, studies in anxiety and major
 depressive disorder 194–5
- emission computed tomography 413
- emotion
 contextual influences 193–4
 perception, development of 78–9
 and serotonin transporter gene 375–8
 understanding of, development of brain circuitry for 82–4
- emotion regulation 38–9
 future research directions 49
 neurobiological correlates
 depression 44–6
 healthy adults 39–43
 healthy children 43–4
 in pediatric anxiety and depression 185–6
 neuroendocrine aspects
 depression 47
 healthy adults and children 46–7
 and stress reactivity 39
- endogenous tracer 428
- endophenotypes 126, 155–6, 367–8, 430
- enhancer 430
- epistasis 430
- epoch 413
- Ernst angle 413
- error-based learning 29–30
- ethical issues
 neuroethics 397–8, 405–6
 theoretical ethics 274–5
 use of PET and SPECT with children 396
see also legal and ethical issues
- event-related fMRI (erfMRI) 284–5, 413
 advantages over block designs 103
 anxiety and MDD studies in adolescents 191–3

- event-related potentials (ERPs) 355, 413
 early language development 91–2
 phonological processing 92–4
 syntactic processing 94
 evolutionary theory of adolescence 53–4
 executive attention 121, 122–3
 executive function *see* cognitive control
 exon 430
 experimental design 283–4
 age-related performance differences, controlling for 394
 block vs. event-related 103, 284–5
 for clinical trials 345–6
 event-related fMRI 191–3, 284–5, 413
 imaging genetic studies 369
 subtractive and additive logic 285
 expressivity 430
 eye contact, development of 78
 eye gaze perception *see* gaze perception
- face perception/processing
 autism studies 138–9
 and theory of mind 140
 brain regions involved in 81–2
 deficits in bipolar disorder (BD) 172
 development of 79
 role of amygdala 172
 in anxiety and depressive disorders 189, 191–2
 in response to fear 82–4
see also gaze perception
- false belief task, theory of mind 80
 fear 183
 amygdala (AMY)
 activation in response to 46, 82–4, 191
 and *HTTLPR* genotypes 377
 role in conditioning of 185–6
 response of infants 79
 feedback-based learning 23, 30–1
 ferromagnetic 413
 fetal alcohol spectrum disorders (FASD) 229–32
 fetal alcohol syndrome (FAS) 229–32
 fiber assignment by continuous tracking (FACT) 317–18, 413
 fiber tractography 317–18
 field of view (FOV) 413
 field strength 282–3, 297, 413
 filtering 413
 flip angle 413
 fluorine-19 (¹⁹F) MRS 302, 310, 413
 fluorodeoxyglucose (FDG) 327, 414
 fluoxetine treatment 347, 357
- FMRI* gene 217, 430
 FMR1 protein (FMRP) 430
 and arithmetic processing 223
 and brain development 218–19
 effect on brain activation 223, 390
 lack of causing fragile X syndrome (FXS) 217
 levels of affecting severity of FXS 218
 and overall cognitive-behavioral problems 219–20
 and white matter changes 221–2
 fMRI relaxometry 124, 414
 FMRI Software Library (FSL) 402
 Food and Drug Administration (FDA), federal regulations
 on conducting research 264, 266–7
 Fourier analysis 323, 414
 fractal triadic model 56–7
 structural basis of
 amygdala 58–9
 prefrontal cortex (PFC) 59–60
 striatum 57–8
 fractional anisotropy (FA) 24, 414
 calculation of 317
 reduced white matter tracts
 in autism 132–3
 in fetal alcohol syndrome 230
 in fragile X syndrome 221
 in schizophrenia 151
 fragile X-associated tremor/ataxia syndrome (FXTAS) 218
 gene-behavior studies 221
 gene-brain-behavior studies 224
 gene-brain studies 222
 fragile X syndrome (FXS) 217
 association with autism 218, 225
 cause of 217
 FMR1 protein and brain development 218–19
 gene-behavior studies 221
 full mutation findings 219–20
 premutation findings 220–1
 gene-brain-behavior studies
 full mutation findings 222–3
 premutation findings 223–4
 gene-brain studies
 full mutation findings 221–2
 premutation findings 222
 molecular research 218
 phenotypical features 217–18
 as a spectrum condition 218
 therapeutic advances 224–5
see also fragile X-associated tremor/ataxia syndrome (FXTAS)

- free induction decay (FID) 296, 414, 422
 repeated free induction decay 423
- FreeSurfer, software 402
- frequency encoding 414
- frontal cortex
 activation deficits in attention deficit/hyperactivity disorder (ADHD) subjects 115–16
 changes in gray matter density (GMD) with maturation 9–10
 effects of S allele of *HTTLPR* 377–8
 glutamatergic neurotoxicity and decreased N-acetylaspartate (NAA) in adolescent bipolar disorder 176
 increased activity during tic suppression 207–8
 and language processing in infants 96
 smaller in ADHD 114, 125
 structural abnormalities in obsessive-compulsive disorder (OCD) and Tourette syndrome (TS) 205–6
see also prefrontal cortex (PFC)
 full mutation 430–1
see also fragile X syndrome (FXS)
- functional magnetic resonance imaging (fMRI) 414
 advantages of perfusion MRI 332–3
 analytic strategies 286
 experimental design 283–4
 block and event-related 284–5
 resting state baselines 285–6
 subtractive and additive logic 285
- language development 96–100
- normal developmental processes 389
- pediatric imaging, special considerations for 287
 differences in cognitive ability 288–9
 fMRI reproducibility issues 289–90
 longitudinal vs. cross-sectional studies 289
 physiological differences between adults and children 287–8
 scanning procedure 287
 spatial normalization 288
 principles of MRI 281–3
 recent advances and future directions 290–1
- functional polymorphism (functional allele) 431
- Funk-Radon transform 320, 414
- fusiform face area (FFA), activation of during face processing 80–1, 138
- fusiform gyrus (FFG), face processing 80–1, 81–2
- FXS *see* fragile X syndrome (FXS)
- FXTAS *see* fragile X-associated tremor/ataxia syndrome (FXTAS)
- gain of function 378, 431
- gamma-aminobutyric acid (GABA) 300, 415
- gaze perception
 autism studies 139, 140
 development of 78, 79
 incongruent vs. congruent paradigm 82
- gene 365–6, 431
- gene dose–response curve 431
- gene expression 431
- general linear model (GLM) 286, 415
- genetic association and linkage 367
- genetic heterogeneity 366, 431
- genetic loci 431
- genetic markers 431
 ancestry-informative markers (AIMs) 369
- genetically complex diseases 367, 369, 430
- genetics 365
 catechol-O-methyltransferase (COMT)
COMT gene and its inherited variations 369–70
COMT Val158Met and frontal cognition
 COMT regulates dopamine level in prefrontal cortex (PFC) 371
 prediction of frontal cognitive performance in varied groups 371–2
COMT Val158Met and stress resiliency
 association with stress resiliency 374
 balancing selection: warrior vs. worrier 373
 stressful stimuli and brain activation 374–5
 effects of COMT on functional neuroimaging measures
 COMT haplotype predicts cortical efficiency 373
Val158Met predicts measures of frontal function 373
- concepts of
 alleles 366
 functional alleles 366
 genes 365–6
 haplotypes 366
- fragile X syndrome 217–25
- future directions 378–9
- gene identification approaches 367
- genetic models of psychiatric diseases 366–7
- imaging genetics and its principles 369
- intermediate phenotypes and endophenotypes 367–9
- of eating disorders (ED) 247–8
- serotonin transporter gene and emotional circuits
 functional 5HTT promoter alleles 375–7
 functional imaging of *HTTLPR* 377–8
 serotonin (5HT) pathway and emotion 375

- genome 367, 431
 genome-wide scan 367, 431
 genomics 431
 genotype, definition 432
 glutamate (Glu) 299–300, 415
 glutamatergic neurotoxicity, adolescent BD 176
 Glx resonance 300, 415
 glycerol phosphocholine (GPC) 300, 415
 glycerophosphoethanolamine (GPE) 300, 415
 goal-directed behavior 53
 approach and avoidance behavior 54–5
 decision-making 55–6
 fMRI paradigms 60–1
 fMRI studies 61–9
 definition of 54
 evolutionary theory 53–4
 fractal triadic model 56–60
 innate vs. learned behaviors 54
 gradient 415
 gradient coils 283, 410
 gradient field 283, 415
 gradient pulses 316, 415
 GRASE (gradient and spin echo) sequence 330, 415
 gray matter density (GMD) 415
 decrease in FXS premutation carriers 222
 normal maturation 149
 asymmetry in 13–15
 brain growth studies 10–12
 cortical pattern matching (CPM) 9–10
 summary of studies 15–16
 volumetric image analysis 5–6
 voxel-based morphometry (VBM) 6–7
 Grimes case, ethical opinion on pediatric research 272–3
 guanine 432
 gyromagnetic ratio (γ) 316, 415, 417, 418, 419
 haplotypes 366, 432
 COMT haplotype and pain threshold 374
 COMT haplotype predicts measures of frontal function 373
 COMT haplotype predicts cortical efficiency 373
 harm avoidance in anorexia nervosa 252
 Health Insurance Portability and Accountability (HIPAA)
 Act of 1996, privacy regulations 271–2
 hemispheric specialization, language processing 100
 hemodynamic response (HR) 415–16
 hemodynamic response function (HRF) 282, 415–16
 heritability 432
 intermediate phenotypes 367–8
 of attention deficit/hyperactivity disorder 126
 of eating disorders 247–8
 of psychiatric disorders 365
 see also genetics
 heterozygous/heterozygote 432
 high angular resolution diffusion imaging (HARDI)
 320, 416
 high *b* value DWI 323, 412
 high field 300, 328–30, 330–1, 416
 hippocampus
 link to schizophrenia 148
 normal development of 15
 role in threat response 186
 volumetric abnormalities
 in adolescent alcohol use disorder (AUD) 235–6
 in bipolar disorder 174
 in major depressive disorder and post-traumatic stress disorder 187, 188
 histone 432
 homogeneity (of a magnetic field) 416
 homozygotes/homozygous 371, 374, 432
 hormonal and neuropeptide influences on eating disorders 247
 Human Brain Project, ASD children 336–7, 339
 hybridization 432
 hypothalamic-pituitary-adrenocortical (HPA) axis
 and emotion regulation 39
 depression due to HPA dysfunction 47
 in healthy adults and children 46–7
 illicit drug use
 adolescent AUD 232–4, 235–8
 prenatal exposure 230, 337–8
 see also substance use disorder (SUD)
 image registration 422
 image selected in vivo spectroscopy (ISIS) 416
 ImageJ, image processing program 405
 imaging genetics 179, 369, 390, 416, 432
 in utero cocaine exposure (IUCE) 337–8
 in vivo MRS 150, 297–302, 310
 “incidental” findings in neuroimaging research 269, 273–4
 indels, genetic markers 431
 informed consent 267, 273–4
 inhomogeneity effects 416
 innate vs. learned behaviors 54
 inorganic phosphate (Pi) 300, 416
 intelligence
 cognitive deficits in adolescent alcohol use disorder (AUD) 235

- intelligence (cont.)
 decline in fragile X syndrome (FXS) 220, 221
 link to morphology 16–17
 relational reasoning 31–3
see also cognitive ability
- intentions of others
 autism studies 140
 biological motion 73, 74, 81, 82
 development of perception of 74
 linking to eye gaze 78
- interference suppression 24–7
- intermediate phenotypes 367–9, 390, 432
- interpulse time 416
- intron (intervening sequence) 432
- inversion 416
- inversion pulse 421
- inversion recovery/inversion recovery
 sequence 416
- inversion time (TI) 416, 427
- isotropic diffusion 416–17
- isotropic voxel 417
- justice, ethics of research 274
- k-space 283, 417
- kilobase (kb) 432
- knockout mice 432
- labeling efficiency 328, 332, 417
- lactate (lactic acid), metabolic marker 299, 417
- lamotrigine treatment for bipolar disorder 356, 357
- language 91, 389
 evidence from event-related potentials 91–2, 94
 early phonological processing 92–4
 early syntactic processing 94
 evidence from fMRI 96–7
 phonological processing 97–8
 evidence from near-infrared spectroscopy 94–5
 higher-level linguistic processing 99–100
 semantic processing 98–9
 syntactic processing 99
 future research directions 103–4
 learning a new language 104
 relating functional and structural brain
 development 103–4
 language skills, link to morphology 17, 103–4
 language stimulation studies, autism 137–8
 methodological issues
 block vs. event-related designs 103
 head motion 103
 interference from scanner noise 103
 summary of imaging studies 100
- Larmor equation 417
- Larmor frequency 296, 417
- lattice 417
- lawsuits 263–4
- learning
 error-based learning 29–30
 feedback-based learning 23, 30–1
 learning effects during task performance 60
 a novel language 104
 stimulus-response (S-R) learning 210–11
- legal and ethical issues 263
 federal regulation of human subjects research
 assent and permission 270–1
 other laws and regulations 271–2
 subpart D, Code of Federal Regulations 264–8
 component analysis 270
 ethical considerations 268–70
 federal regulatory agencies 264
 lawsuits and regulations 263–4
 paradigm case studies and applied ethics 275
 standards of care 273–4
 state law
 state court cases and the Grimes opinion 272–3
 state statutes 272
 theoretical ethics 274–5
- liability, genetics 432
- Linear Combination of Model (LCModel) spectra 303–5
- linkage, genetic 367, 432
- linkage disequilibrium (LD) 366, 432
- lithium-7 (^7Li) MRS 302, 310, 417
- lithium treatment for bipolar disorder 177, 355–6
- locus/loci 367, 432
- longitudinal relaxation 417
- longitudinal relaxation time (T_1) 417, 423, 426
- longitudinal studies, critical need for 393–5
- low birth weight, risk factor in eating disorders 248
- lymphoblasts 432
- magnet coils 410
- magnetic field gradient 417
- magnetic field inhomogeneity effects 416
- magnetic field strength 282–3, 328–30, 417
- magnetic moment 417
- magnetic resonance 417
- magnetic resonance imaging (MRI) 417–18
 limitations of 314–15

- principles of 281
 blood-oxygen-level-dependent (BOLD) contrast 281–2
 magnetic strength 282–3
see also structural MRI (sMRI)
- magnetic resonance spectroscopy (MRS) 296, 418
 advances and future directions 310–11
 anatomical localization of 302
 anxiety and depression 194
 application of
 healthy brain development 305
 phosphorus MRS 306–9
 proton MRS 306
 pediatric psychiatric disorders 309
 lithium and carbon MRS 310
 phosphorus MRS 310
 proton MRS 309–10
 autism studies 133–6
 in vivo studies of normal brain development 150
 limitations of 305
 methods 297
 other MR visible nuclei 300–2
 phosphorus (^{31}P) MRS 300
 proton (^1H) MRS 297–300
 principles of 296–7
 schizophrenia studies 153–4
 spectral analysis and quantification 303–5
 technological advances 391
- magnetic susceptibility 333, 418, 419
 magnetization transfer 418
 major depressive disorder (MDD) *see* depression
 malpractice 263–4
 manipulation, working memory 27
 marijuana use, alcohol use disorder subjects 235–8
 marker 432
 mean diffusivity 418, 428
 medial prefrontal cortex (mPFC), implicated in theory
 of mind and self-reflection 81, 84
 Medical Imaging Processing Analysis and
 Visualization (MIPAV) 405
 meiosis 432
 memory
 role in mood/emotion regulation 42–3
 Sternberg memory search task paradigm 285
see also working memory (WM)
- mental chronometry 285, 409
 mental retardation, inheritance of *see* fragile
 X syndrome (FXS)
 mentalization *see* theory of mind (ToM)
 messenger RNA (mRNA) 218, 365, 370, 432–3, 434
 metabolite ratios, measuring 305, 311
 metabotropic glutamate receptor (mGluR) theory of
 fragile X syndrome (FXS) 433, 407
 methylation 433
 methylphenidate (MPH)
 and cerebral blood flow (CBF) 350
 effect on synaptic dopamine 350
 effects on children with attention deficit/hyperactivity
 disorder 351–5
 microarray 433
 microRNAs (miRNAs) 433
 microsatellites, genetic markers 431
 minisatellites, genetic markers 431
 mirror neuron system (MNS)
 autism studies 140–2
 and perception of biological motion 81
 mismatch negativity (MMN) response,
 phonological processing 93
 missense variant (missense mutation) 433
 monozygotic 433
 mood-stabilizing medication for bipolar disorder,
 effects of 176–7
 mood states, cognitive strategies for regulating 40–3
 morphological development of the brain 5
 anxiety and depressive disorders 187
 data from juveniles 188
 findings from adult studies 187–8
 and cognition 16–17
 normal morphological maturation
 cortical pattern matching (CPM) 7–9
 brain surface asymmetry 12–15
 cortical expansion 10–12
 gray matter density (GMD) 9–10
 subcortical growth 15
 summary of findings 15–16
 volumetric image analysis 5–6
 voxel-based morphometry (VBM) 6–7
 mosaic 433
 motion compliance training 287
 motion correction 287
 MR sensitivity/visibility 418
 MRICro, brain image tool 402
 multi-compartment perfusion models 332, 418
 mutation 433
 myelination, and cortical expansion 11–12
myo-inositol (mI) 298, 306, 309–10, 418
N-acetylaspartate (NAA) 418
 in vivo proton ^1H spectroscopy 150, 297–8

- N*-acetylaspartate (NAA) (cont.)
 increased levels with age 306
 reduced levels in pediatric psychotic disorders
 306, 309
 bipolar disorder (BD) 174, 176
 schizophrenia 153, 309
 MRS studies of autism 136
- narrative comprehension, neural underpinnings
 of 99–100
- National Alliance for Medical Image Computing
 (NA-MIC) 392, 404
- National Centers for Biomedical Computing 404
- National Commission 263
 Belmont Report, deontological theories of ethics 274–5
- National Database for Autism Research (NDAR) 392, 403
- National Library of Medicine Insight Segmentation and
 Registration Toolkit (ITK) 405
- Near-infrared spectroscopy (NIRS) 392, 418
 early language development 94–5
- negligence 263, 273–4
- neuroethics 397–8, 405–6
- Neuroimaging Informatics Tools and Resources
 Clearinghouse (NITRC) 392, 403–4
- neuroinformatics 392–3, 403
- NeuroLens, analysis tool 402
- neuropeptides, and eating disorders 247, 249
- neurotransmitter systems
 measurement of 299–300, 391
 limitation in children 396
 receptor imaging studies, eating disorders 250–2
 risk factor in eating disorders 248–9
 role in attention deficit/hyperactivity disorder
 (ADHD) 125
 schizophrenia studies 156
see also dopamine (DA); serotonin (5HT)
- neutral polymorphisms 433
- NIH Pediatric MRI Data Repository 403
- NIRS *see* near-infrared spectroscopy (NIRS)
- non-synonymous polymorphism 433
- nuclear magnetic resonance imaging *see* magnetic
 resonance imaging (MRI)
- nuclear magnetic resonance (NMR) 418–19
- nuclear magnetic resonance spectroscopy (NMRS)
see magnetic resonance spectroscopy (MRS)
- nuclear spin 419
- nucleolar RNAs 433
- nucleolus 433
- nucleoside triphosphate (NTP) 300, 309, 419
- nucleosome protein cores 366, 433
- nucleotides (bases) 433
- nucleus, definition and role in MRS 296–7, 433
- obsessive-compulsive disorder (OCD) 199
 anatomical disturbances 205–6
 comorbidity with other disorders 200
 functional disturbances 208–10
 neural basis of 200–3
 paroxetine treatment 357–61
 relationship to Tourette syndrome 200
 role of fronto-striatal systems 212
 selective serotonin reuptake inhibitors (SSRIs) and
 cognitive behavioral therapy 357–61
 stimulus-response (S-R) learning 211
see also Tourette syndrome (TS)
- odds ratio 433
- Office for Human Research Protections (OHRP),
 responsibility of 264
- olanzapine treatment for bipolar disorder (BD)
 177, 356, 357, 390
- orbitofrontal cortex (OFC)
 and compulsions in obsessive-compulsive disorder
 (OCD) 206
 and decision-making 61
 and learned responses 54
 role in emotion regulation 44–5
 role in reward anticipation 61
- orientation distribution function (ODF) 320, 419
- outer volume suppression (OVS) 419
- pain perception
 effect of COMT haplotype on pain threshold 374
 effects of placebo analgesia 346–7
- panic disorder, treatment of 357
- parallel imaging 330, 419
- paramagnetic 419
- parcellation 419
- parental permission (informed consent) 270–1
- paroxetine treatment for OCD 357–61
- partial volume effect 419
- pediatric imaging issues 287
 cross-site and longitudinal studies, fMRI
 reproducibility 289–90
 differences in cognitive ability 288–9
 ethical constraints on use of PET and SPECT 396
 longitudinal vs. cross-sectional studies 289
 physiological differences between children and
 adults 287–8
 scanning procedures 287, 322

- spatial normalization 288
- use of sedation 397
- see also* legal and ethical issues
- penetrance 430, 433–4
- performance monitoring 29–31
- perfusion fMRI, advantages over BOLD fMRI 332–3
- permission *see* parental permission (informed consent)
- phantom (coil loading) 305
- pharmacologic MRI (phMRI) 396
- phase encoding 419
- phased array coils 330, 409
- phenotypes 434
 - anorexia nervosa 245
 - anxiety disorders 183–4
 - brain phenotypes 86–7
 - bulimia nervosa 245–6
 - depressive disorders 184
 - see also* endophenotypes; intermediate phenotypes
- philosophy of ethics 274–5
- phobias
 - and amygdala dysfunction 189
 - treatment of 357
 - see also* social phobia (SOPH)
- phonological processing
 - and cortical thickening 17, 389
 - event-related potential (ERP) studies 92–4
 - fMRI evidence 97–8
- phosphocreatine (PCr) 287, 298, 309, 419
- phosphodiesterases (PDE) 300, 306–9, 420
- phosphomonoesters (PME) 300, 420
 - changes in ratio of PME/PDE 306–9
 - reduced levels in schizophrenia 153–4, 310
- phosphorus (³¹P) MRS 150, 300, 420
 - healthy brain development 306–9
 - pediatric psychiatric disorders 310
- physiological noise 287–8
- placebo effect 346–7
- planes of the brain 420
- pleiotropy, definition 434
- point-resolved spectroscopy (PRESS) 302, 420
- polygenicity 366–7, 434
- polymorphisms 247–8, 365, 434
- positron emission tomography (PET) 420
 - attention deficit/hyperactivity disorder (ADHD) studies 119–20, 121, 123, 124
 - effects of stimulants and non-stimulants 347–50
 - autism studies 136–7, 137–8, 139–40, 142
 - brain glucose metabolism in depression 347
 - cognitive control studies 149–50
 - eating disorder studies 249
 - ethics preventing use on children 345, 397–8
 - obsessive-compulsive disorder studies 208–9
 - and serotonin transporter binding 375–6
- precession 420
- preference formation/selection 68
- prefrontal cortex (PFC)
 - adults with anxiety and depression 188, 191
 - COMT regulating dopamine level in 371
 - and development of emotion regulation 43–4
 - and goal-directed behaviors 59–60
 - modulating stimulus-reinforcement associations 186
 - role in cognitive control functions 23–4
 - role in reappraisal 40
 - see also* dorsolateral prefrontal cortex; frontal cortex; orbitofrontal cortex ventral prefrontal cortex
- premutation 434
 - in fragile X syndrome
 - gene-behavior studies 220–1
 - gene-brain-behavior studies 223–4
 - gene-brain studies 222
 - see also* fragile X-associated tremor/ataxia syndrome (FXTAS)
- prenatal alcohol exposure
 - brain structural abnormalities 230–2
 - developmental effects 229–30
- probabilistic brain atlas 154, 420
- probabilistic classification learning (PCL) 210–11
- probability density functions (PDFs) 320, 420
- probability distribution 420–1
- probability in decision-making 60
- proband 434
- prognostication 155
- promoters 366, 375, 434
- prosody processing, brain lateralization 100
- protected health information (PHI), privacy regulations 271–2
- protein 434
- proton (¹H) MRS 150, 297–300, 421
 - and pediatric psychiatric disorders 309–10
 - studies of healthy brain development 306
- proton decoupling 300, 421
- proton density (ρ) 421
- pseudo-continuous ASL (pseudo-CASL) 328, 332, 421
- psychotherapy, effects on the brain 347, 357–61
- pulse 90° 421, 423
- pulse 180° 416, 421
- pulse sequence 421

- pulse sequence programming 421
 pulsed arterial spin labeling (PASL) perfusion imaging 328, 332, 421
- q-ball imaging 421
 q-space imaging 323, 422
 quantitative electroencephalography (qEEG) 195, 422
- raclopride 349–50, 422
 radiofrequency (RF) 422
 radiofrequency (RF) coil 409
 radiofrequency (RF) pulse 281, 421, 422
 radioisotope 422
 radioligands 250–2, 422
 reasoning ability 31–3
 recombination 434
 recovery (relaxation) 296, 422
 region of interest (ROI) 286, 422
 regional cerebral blood flow (rCBF)
 autism studies 136–7, 339
 normal development 335–6
see also cerebral blood flow (CBF)
- registration 422
 relational reasoning 31–3
 relative anisotropy (RA) 422
 relaxation 422
 relaxation rates 422
 relaxation times 422
 repeat number polymorphism 434
 repeated free induction decay 423
 repetition time (RT) 423
 rephase/rephasing pulse 423
 rephasing gradient 423
 research legislation
 federal laws and regulations 264–72
 state law 272–3
 resonances 423
 resources
 educational 401
 neuroethics 405–6
 neuroinformatics 403
 software 401–2
 response inhibition 27–8
 in attention deficit/hyperactivity disorder (ADHD) 115–19
 in fragile X syndrome (FXS) 223
 in Tourette syndrome and obsessive-compulsive disorder, role of fronto-striatal systems 211–12
 neural correlates of 172
 response selection 28–9, 34
 resting state networks 285–6, 395
 resting state studies
 attention deficit/hyperactivity disorder (ADHD) 124, 350
 autistic spectrum disorders (ASDs) 136–7
 obsessive-compulsive disorder (OCD) 208–9
 reward processing
 adolescent responses to outcome 68–9
 anticipation of monetary reward 61–8
 eating disorders
 anorexia and 5HT2A-1438A/A allele 247
 bulimia and anterior cingulate response 252
 role of dopamine 247
 preference formation/selection phase 68
 primary vs. secondary reward 60
 role of striatum 61, 124, 174, 186, 206
 stimulus-response (S-R) learning 186
see also decision-making
 ribonucleic acid (RNA) 366, 434
 ribosome 434
 RNA polymerase enzyme 366, 434
 RNA toxicity 221, 434
- saturation 423
 saturation pulse 421
 saturation recovery (SR) 423
 schizophrenia 147–8
 brain development 148–9
 cognitive control 152
 cortical inefficiency of Val allele carriers 372–3
 diagnostic value of neuroimaging 155
 neurobiology of 148–9
 neuroimaging research 155
 etiopathology 155–6
 methodologic issues 154–5
 treatment implications 156
 neuroimaging studies 390
 brain function, changes in 152–3
 brain structure, changes in 150–1
 connectivity, changes in 151
 neurochemical brain alterations 153–4, 309, 310
 pathophysiological models of 148
 prognostic value of neuroimaging 155
 and working memory 152, 371
 Secretary's Advisory Committee on Human Research Protections (SACHRP) 268–9
 seeding region of interest (seeding ROI) 317, 320–1, 423–4
 selective attention 22, 120, 121–2

- selective serotonin reuptake inhibitors (SSRIs)
 and cognitive behavioral therapy in OCD 357–61
 and serotonin transporter function 375
 treatment of bulimia nervosa (BN) 254
- self-reflection, role of medial prefrontal cortex 81, 84
- semantic processing
 event-related potential studies 93–4
 evidence from near-infrared spectroscopy 98–9
- sequence delay time 424
- serotonin (5HT)
 and emotion 375
 risk factor for eating disorders 247
- serotonin transporter gene (*5HTT*) 375
 functional 5HTT promoter alleles
 functional promoter polymorphism (*5HTTLPR*) 375
HTTLPR predicts anxiety and dysphoria 376–7
 a third common, functional *HTTLPR* allele 375–6
 functional imaging of *HTTLPR*
 genotypes alter amygdala/frontal cortex coupling 377
 effect of *S* allele on amygdala-prefrontal cortex
 coupling 377–8
 stronger amygdala activation/volume 377
- sex differences
 amygdala development 83
 brain activation in adolescent alcohol use disorder 236
 brain metabolites 309
 hippocampal volumes in bipolar disorder 174
 in cerebral metabolic rate of glucose (CMRGlc) in
 attention deficit/hyperactivity disorder
 (ADHD) 121
- shim coils 424
- shimming 424
- sickle cell disease (SCD) 338–9
- signal attenuation, diffusion tensor imaging 424
- signal averaging 424
- signal loss 316, 424
- signal-to-noise ratio (SNR) 424
 arterial spin labeling (ASL) imaging 328–30
- single nucleotide polymorphisms (SNPs) 369–70, 431, 435
- single photon emission computed tomography
 (SPECT) 424
 abnormal dopaminergic transmission in TS 201–3
 autism studies 136–7
 cerebral blood flow after methylphenidate (MPH)
 treatment 350
 ethical constraints on use with children 345, 396
 fronto-striatal hyperactivity in obsessive-compulsive
 disorder (OCD) 208–9
 task activation studies in bulimia nervosa 252
- single-shot radiofrequency excitation 330, 424
- single-voxel magnetic resonance spectroscopy 302,
 310, 391, 424
- slice selection 424
- smoothing 424–5
- social cognition 73–4
 brain mechanisms 80
 functional connectivity 85–6
 social perception 80–1
 theory of mind and self cognition 81
- development of
 perceiving emotions 78–9
 perceiving eye gaze 78
 theory of mind (ToM) 79–80
 understanding others' goals and intentions 74
- functional neuroimaging
 emotion understanding 82–4
 social perception 81–2
 theory of mind (ToM) 84–5
 value of developmental approach 86–7
- social perception
 brain regions involved in 80–1
 functional neuroimaging of 81–2
 early development of 74
- social phobia (SOPH)
 imaging studies showing activation 189–91
 enhanced amygdala activation 189
- sodium-23 (^{23}Na) MRS 301, 425
- software tools for image analysis 286, 303–4, 401–2, 405
- spatial frequency filtering 425
- spatial normalization 288, 425
- spatial resolution 23, 302, 389, 425
- spatial smoothing *see* smoothing
- specific absorption rate (SAR) 425
- spectroscopic imaging (SI) 302, 409, 425
- speech processing 95, 96, 137–8
- spin 425
- spin axes 425
- spin coupling 425
- spin density 421, 425
- spin echo 425–6
- spin labeling schemes 328
- spin lattice relaxation 417
- spin-lattice relaxation time 423, 426, 428
- spin-quantum number 426
- spin-spin broadening 426
- spin-spin relaxation time 423, 426
- spin-spin splitting 426
- spiral sequences/imaging 283, 426

- standards of care 273–4
- Statistical Parametric Mapping (SPM), software 402
- stereotaxic/stereotaxic space 132, 426
- stimulated echo acquisition (STEAM) 302, 426
- stimulus-response learning in TS and OCD 210–11
- stream-tubes 426
- stress reactivity
 COMT Va1158Met genotype and stress
 resiliency 373–5
 effects of *HTTLPR S* allele on stress exposure
 376–8, 377–8
 and emotion regulation 39
 role of hypothalamic-pituitary-adrenocortical
 (HPA) axis
 in depression 47
 in healthy adults and children 46–7
- striatum
 abnormalities in bipolar disorder 174–5
 decreased blood flow in boys with attention
 deficit/hyperactivity disorder (ADHD) 124
 fractal triadic model 57–8
 implicated in Tourette syndrome and obsessive-
 compulsive disorder circuitry 201–3, 211–12
 role in reward processing 124, 174
 role in S-R learning 210, 211
 structural abnormalities in ADHD 125
see also caudate nucleus; ventral striatum
- structural MRI (sMRI)
 ADHD studies 114, 351
 adolescent alcohol use disorder 236
 autism studies 131–2
 bipolar disorder studies 173
 eating disorders (EDs) 249
 fragile X syndrome 221
 legal implications 398
 morphometry comparisons 187–8, 418
 normal brain development 149, 288, 389
 NIH Pediatric MRI Data Repository 403
 obsessive-compulsive disorder studies 205–6
 prenatal alcohol exposure 230–2
 schizophrenia studies 150–1
see also magnetic resonance imaging (MRI)
- substance use disorders (SUD) 232
 cognitive deficits 235
 comorbidity with behavior disorders 234
 models of development of 232–4
see also adolescent alcohol use disorder (AUD);
 illicit drug use
- subtraction technique 427
- subtractive logic 285
- superior temporal sulcus (STS) 81
 abnormalities in autism 132, 137
 eye gaze processing 140
 in voice-selective areas of STS 139
 mentalization/theory of mind 140
- biological motion 82
 face sensitivity region 82
 intentions of actions 82
- surface coil 409
- susceptibility artifacts 427
- susceptibility gene 435
- sustained attention 120, 121
- syntactic processing
 event-related potential studies 94
 fMRI studies 99
- T_1 relaxation time 423
- T_1 -weighted MRI 427
- T_2 relaxation time 423
- T_2 -weighted MRI 427
- T_2^* 408, 423, 426
- tagging efficiency *see* labeling efficiency
- Talairach coordinates 427
- TE (time to echo) 427
- technological advances
 imaging modalities 391–2
 neuroinformatics 392–3
- temporal parietal junction (TPJ), implicated in theory
 of mind 81, 85
- temporal resolution 92, 195, 283–4, 427
- terminology
 genetic terms 428–35
 imaging terms 407–28
- Tesla 282–3, 427
- test-retest reliability, longitudinal studies 394
- theory of mind (ToM) 73, 79–80
 autism studies 139–40
 and eye contact 78
 functional neuroimaging 84
 behavioral vs. imaging studies, age-related
 differences 84–5
 and self cognition 81
- threats, brain response to 185–6
- thymine 435
- TI (time to inversion) 427
- tics *see* Tourette syndrome (TS)

- tissue segmentation 6, 305, 427
- Tourette syndrome (TS) 199
 anatomical disturbances 203–5
 functional disturbances 207–8
 neural circuitry 200–3, 390
 phenomenology 199–200
 stimulus-response learning 210–11
see also obsessive-compulsive disorder (OCD)
- TR (time to repetition) 427
- trace (D) 316–17, 428
- tracer half-life, blood T1 327, 328, 331
- tracers 326, 428
- tractography 317–18, 319, 428
- trait behaviors, risk factor for eating disorders 248
- transcranial Doppler sonography (TCD) 338, 428
- transcranial magnetic stimulation (TMS) 290–1, 428
- transcription 366, 435
- transcription factors 435
- transfer RNA (tRNA) 435
- translation 435
- transmission disequilibrium test 435
- transverse magnetization 428
- transverse relaxation time 423, 426, 428
- treatment effects 344
 effects of placebo and cognitive behavioral therapy (CBT) on brain function 346–7
 future directions 361
 methodological issues 345–6
- treatment responses
 mood stabilizers and antipsychotics in bipolar disorder
 functional and anatomic MRI 356–7
 magnetic resonance spectroscopy (MRS) 355–6
 normalizing neural circuitry 176–7
 potential type 1 biomarkers 357
- selective serotonin reuptake inhibitors (SSRIs) and CBT in obsessive-compulsive disorder 357–61
 potential type 1 biomarkers 361
- stimulant and non-stimulant effects in ADHD
 anatomic MRI 351
 event-related potentials (ERPs) 355
 functional MRI 351–5
 PET studies 351
 potential type 1 biomarkers 355
see also treatment effects
- trinucleotide repeat expansion 217, 435
- triplet repeat expansion 435
- utilitarianism, ethical issues 274–5
- variance, attempts to reduce inter-site sources of 395
- velocardiofacial syndrome (VCFS) 372, 429
- ventral prefrontal cortex (VPMC)
 changes during adolescence 171–2
 dysfunction in bipolar disorder 175–6, 178
 effects of olanzapine monotherapy 177
 effects of psychotropic medication 356
 increased activation with lithium therapy 177
- ventral striatum 57, 59
 abnormalities in bipolar disorder 174–5
 and reward expectancy 206
- visuospatial working memory (VSWM) 24–7
 females with FXS 223
- voice perception, autism studies 139–40
- volumetric image analysis 5–6
- voxel 428
- voxel-based morphometry (VBM) 428
 autism studies 132
 bipolar disorder studies 174–5
 schizophrenia studies 150–1
 studies of normal development 6–7
- voxelwise 428
- white matter
 autism studies 132–3, 314
 density increase with age 7, 11
 DTI fiber tractography 317–18
 enlargement in FXS 222
see also diffusion tensor imaging (DTI); fractional anisotropy (FA)
- Williams syndrome 55
- working memory (WM)
 developmental studies of 24
 effect of *Val158Met* in healthy adults 371
 effects of chronic alcohol exposure 236–8
 enhanced by dopamine 371
 in ADHD studies 119–20, 372
 and manipulation 27
 schizophrenia studies 152, 371
 visuospatial working memory 24–7, 223
- X-chromosome 435
- X inactivation 435
- X-inactivation ratio 220, 435